CASTRES, France, June 28, 2010 /PRNewswire/ — Mr Jean-Pierre Garnier will step down on
September 1st 2010, two years after
having been appointed CEO of the Pierre Fabre Group.
“The Company is in excellent health, and is poised to experience
a bright future ; I am glad to have contributed to its success and
I take this opportunity to thank Mr. Pierre
Fabre, visionary founder, for having entrusted me with this
important mission”.
Mr. Pierre Fabre thanked Mr Jean-Pierre Garnier for his “commitment
and the excellent work performed” and stated that “his contribution
over the past two years has been of the utmost benefit to the
Company”.
The new governance, which will continue in the spirit of the
current organisation, will be announced in the near future.
About Pierre Fabre group :
The Pierre Fabre Group, the second largest independent French
pharmaceutical company and leader in the field of in-pharmacy
dermocosmetics, employs about 10,000 people worldwide, including 1,400 R&D
staff, and generates a turnover of EUR 1.8 billion.
In 2009, Pierre Fabre Medicament dedicated 28% of its annual turnover to
R&D in four priority therapeutic areas in public health: oncology, central
nervous system, dermatology, cardio-vascular/metabolism.
To learn more about Pierre Fabre, please refer to
http://www.pierre-fabre.com.
Press Contact :
Djamila Hazene-Kedjem
‘/>”/>
